EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSLCAG00010013639
Gene Symbol: GABRG3
2 Cross references
215 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSLCAG00010023477
Gene Symbol: GABRG3
4 Cross references
214 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLCAG00010008757
Gene Symbol: GABBR1
4 Cross references
190 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSLCAG00010001724
Gene Symbol: GABBR1
4 Cross references
197 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSLCAG00010015647
Gene Symbol: GLP2R
4 Cross references
204 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSLCAG00010007856
Gene Symbol: GCGR
1 Cross references
164 Possible Orthologues:

Glucokinase (Hexokinase 4)

Ensembl ID : ENSLCAG00010001272
Gene Symbol: LOC108881204
4 Cross references
211 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSLCAG00010025081
Gene Symbol: GBA1
4 Cross references
251 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSLCAG00010024217
Gene Symbol: GRIN1
4 Cross references
178 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSLCAG00010002791
Gene Symbol: GRIN2A
1 Cross references
228 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSLCAG00010012442
Gene Symbol: GRIN2B
2 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2c

Ensembl ID : ENSLCAG00010013500
Gene Symbol: GRIN2C
1 Cross references
115 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).